Comparison of efficacy of pembrolizumab plus carboplatin plus chemotherapy versus pembrolizumab as a first line treatment in patients with advanced non-small cell lung cancer
Latest Information Update: 16 Jul 2021
At a glance
- Drugs Pembrolizumab (Primary) ; Antineoplastics; Carboplatin
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 16 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology